Skip to main content

Table 2 Incidence of acute intestinal GvHD > grade 2 until day 100 (p = 0.888 n.s.)

From: Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)

  Group Total
Placebo Budesonide
Acute intestinal GvHD grade 0-2 Number 37 42 79
% 86.0% 87.5% 86.8%
Acute intestinal GvHD grade 3-4 Number 6 6 12
% 14.0% 12.5% 13.2%
Total 43 48 91